Low prevalence of influenza A strains with resistance markers in Brazil during 2017–2019 seasons

dc.creatorSousa, Thiago das Chagas
dc.creatorMartins, Jessica Santa Cruz Carvalho
dc.creatorMiranda, Milene Dias
dc.creatorGarcia, Cristiana Couto
dc.creatorResende, Paola Cristina
dc.creatorSantos, Cliomar A.
dc.creatorDebur, Maria do Carmo
dc.creatorRodrigues, Rodrigo Ribeiro
dc.creatorCavalcanti, Andrea Cony
dc.creatorGregianini, Tatiana Schäffer
dc.creatorIani, Felipe Campos de Melo
dc.creatorPereira, Felicidade Mota
dc.creatorFernandes, Sandra Bianchini
dc.creatorFerreira, Jessylene de Almeida
dc.creatorSantos, Katia Correa de Oliveira
dc.creatorMotta, Fernando
dc.creatorBrown, David
dc.creatorAlmeida, Walquiria Aparecida Ferreira de
dc.creatorSiqueira, Marilda Mendonça
dc.creatorMatos, Aline da Rocha
dc.date2023-02-01T15:28:43Z
dc.date2023-02-01T15:28:43Z
dc.date2022
dc.date.accessioned2023-09-26T20:56:40Z
dc.date.available2023-09-26T20:56:40Z
dc.identifierSOUSA, Thiago das Chagas et al. Low prevalence of influenza A strains with resistance markers in Brazil during 2017–2019 seasons. Frontiers in Public Health, 10, 944277, p. 1 - 9, Sept. 2022.
dc.identifier2296-2565
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/56816
dc.identifier10.3389/fpubh.2022.944277
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8866582
dc.descriptionThe influenza A virus (IAV) is of a major public health concern as it causes annual epidemics and has the potential to cause pandemics. At present, the neuraminidase inhibitors (NAIs) are the most widely used anti-influenza drugs, but, more recently, the drug baloxavir marboxil (BXM), a polymerase inhibitor, has also been licensed in some countries. Mutations in the viral genes that encode the antiviral targets can lead to treatment resistance. Worldwide, a low prevalence of antiviral resistant strains has been reported. Despite that, this situation can change rapidly, and resistant strain surveillance is a priority. Thus, the aim of this was to evaluate Brazilian IAVs antiviral resistance from 2017 to 2019 through the identification of viral mutations associated with reduced inhibition of the drugs and by testing the susceptibility of IAV isolates to oseltamivir (OST), the most widely used NAI drug in the country. Initially, we analyzed 282 influenza A(H1N1)pdm09 and 455 A(H3N2) genetic sequences available on GISAID. The amino acid substitution (AAS) NA:S247N was detected in one A(H1N1)pdm09 strain.We also identifiedNA:I222V (n=6) andNA:N329K (n = 1) in A(H3N2) strains. In addition, we performed a molecular screening for NA:H275Y in 437 A(H1N1)pdm09 samples, by pyrosequencing, which revealed a single virus harboring this mutation. Furthermore, the determination of OST IC50 values for 222 A(H1N1)pdm09 and 83 A(H3N2) isolates revealed that all isolates presented a normal susceptibility profile to the drug. Interestingly, we detected one A(H3N2) virus presenting with PA:E119D AAS. Moreover, the majority of the IAV sequences had the M2:S31N adamantanes resistantmarker. In conclusion, we show a low prevalence of Brazilian IAV strains with NAI resistance markers, in accordance with what is reported worldwide, indicating that NAIs still remain an option for the treatment of influenza infections in Brazil. However, surveillance of influenza resistance should be strengthened in the country for improving the representativeness of investigated viruses and the robustness of the analysis.
dc.formatapplication/pdf
dc.languageeng
dc.publisherFrontiers Media
dc.rightsopen access
dc.subjectVírus da gripe A
dc.subjectInibidores da neuraminidase (NA)
dc.subjectOseltamivir
dc.subjectBaloxavir marboxiL
dc.subjectAdamantano
dc.subjectResistência
dc.subjectInfluenza A virus
dc.subjectNeuraminidase (NA) inhibitors
dc.subjectOseltamivir
dc.subjectBaloxavir marboxiL
dc.subjectAdamantane
dc.subjectResistance
dc.titleLow prevalence of influenza A strains with resistance markers in Brazil during 2017–2019 seasons
dc.typeArticle


Este ítem pertenece a la siguiente institución